Details of the Drug Combinations

General Information of This Drug (ID: DM2LU8M)

Drug Name

AP1903 DM2LU8M

Synonyms

Rimiducid; AP1903; 195514-63-7; UNII-H564L1W5J2; AP 1903; AP-1903; H564L1W5J2; Rimiducid [INN]; Rimiducid [USAN:INN]; CHEMBL269259; SCHEMBL10111062; DTXSID80173226; EX-A1711; AKOS030238859; CS-3162; KB-74710; HY-16046; Z-3163; 2-Piperidinecarboxylic acid, 1-(1-oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-(3,4-dimethoxyphenyl)propylidene)) ester, (2S-(1(R*),2R*(S*(S*(1(R*),2R*)))))-

Indication

Disease Entry	ICD 11	Status	REF
Transplant rejection	NE84	Phase 1/2	[1]
------------------------------------------------------------------------------------

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
AP1903 + Cyclophosphamide	DC37J6Q	Cyclophosphamide	Lymphoma	[2]
AP1903 + Cyclophosphamide	DC7IT1W	Cyclophosphamide	Myeloma-Multiple	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01744223) Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
3	ClinicalTrials.gov (NCT03958656) T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma